Abstract:OBJECTIVE:To investigate the relationship between the expression of DDX39 protein and prognosis in colorectal cancer.METHODS:Clinical data and paraffin specimens of postoperative tumor tissue from 824 patients with primary colorectal cancer who received first surgical treatment at the Department of Colorectal Surgery of Changhai Hospital of Navy Military Medical University from January 2010 to December 2011 were collected. Paraffin samples of paracancerous tissues of 38 patients were served as controls. At the same time, samples of normal rectal mucous membrane from 37 cases after procedure of prolapse and hemorrhoids, and samples of colorectal adenoma from 33 cases after endoscopic treatment were enrolled in this study. All the specimens were made as the tissue microarray, and the expression of DDX39 protein was detected by immunohistochemistry. The expression of DDX39 in the epithelium and stroma was evaluated with the average staining intensity (H-Score) and the number of positive cells. It was defined as high expression in the epithelium that the H-Score was greater than or equal to 200. It was defined as high expression in the stroma that the number of positive cells was greater than or equal to 50 in 200 times the field of vision. Relationship of different DDX39 expression levels with clinicopathological parameters and prognosis of colorectal cancer was analyzed.RESULTS:The expression of DDX39 in colorectal cancer tissues was lower than that in normal tissues, paracancerous tissues and adenomatous tissues, whether it is in the epithelium or in the stroma [DDX39 expression in the epithelium: normal tissues 253.2±64.1, paracancerous tissues 238.8±79.2, adenomatous tissues 259.4±51.6, colorectal cancer tissues 194.2±76.5 (P=0.000, P=0.005, P=0.000, respectively); DDX39 expression in the stroma: normal tissues 110.1±64.8, paracancerous tissues 106.0±49.2, adenomatous tissues 108.5±79.1, colorectal cancer tissues 54.1±34.7(all P=0.000)]. Among the cases of colorectal cancer, there were 541 cases of high DDX39 expression and 283 cases of low DDX39 expression in the epithelium; there were 424 cases of high DDX39 expression of and 400 cases of low DDX39 expression in the stroma. The high DDX39 expression and low DDX39 expression in epithelial and stromal of colorectal cancer were related respectively with tumor location (P=0.006, P=0.016), degree of tumor differentiation (P=0.002, P=0.064), TNM stage (P=0.021, P=0.000), serum CEA level (P=0.003, P=0.005), serum CA199 level (P=0.040, P=0.005) and tumor recurrence and metastasis (P=0.000, P=0.000). All the colorectal cancer cases were followed up for (41.6±15.7) months after operation. The 5-year overall survival (OS) and disease-free survival (DFS) rates of the cases with epithelial low DDX39 expression were 84.1% and 61.5%, and both were significantly lower as compared to those with epithelial high DDX39 expression (95.4% and 88.2%, P=0.000, P=0.000). The 5-year OS and DFS rates of the stroma low DDX39 expression were 86.8% and 66.8%, and both were significantly lower as compared to those with stroma high DDX39 expression (96.1% and 90.6%, P=0.000, P=0.000). Cox multivariate analysis showed that tumor differentiation (OS:HR=0.252, 95%CI: 0.128 to 0.497, P=0.000; DFS:HR=0.266, 95%CI: 0.134 to 0.530, P=0.000), DDX39 expression level in epithelium (OS: HR =0.229, 95%CI: 0.138 to 0.382, P=0.000; DFS: HR =0.266, 95%CI: 0.158 to 0.446, P=0.000), and DDX39 expression level in stroma (OS: HR =0.331, 95%CI: 0.188 to 0.582, P=0.000; DFS:HR=0.326, 95%CI: 0.184 to 0.578, P=0.000) were independent influencing factors of overall or disease-free survival in patients with colorectal cancer.CONCLUSION:The low expression of DDX39 protein suggests poor prognosis and DDX39 is expected to be a new prognostic marker of colorectal cancer.

PTH-94 DRIM expression in colorectal cancer and its possible tumour suppressive role, clinical and prognostic significance

Comprehensive profiling of the TRIpartite motif family to identify pivot genes in hepatocellular carcinoma

TRIM29 is Differentially Expressed in Colorectal Cancers of Different Primary Locations and Affects Survival by Regulating Tumor Immunity Based on Retrospective Study and Bioinformatics Analysis

High TRIM59 Expression Predicts Adverse Outcomes and is Correlated with Immune Infiltrates in Lung Adenocarcinoma

Integrated Bioinformatics Analysis Reveals Correlations of High TRIM59 Expression with Worse Prognosis and Immune Infiltrates in Lung Adenocarcinoma

Correlation Between Tripartite Motif-Containing Protein 44 Protein Expression and the Prognosis of Postoperative Patients Exhibiting Skin Squamous Cell Carcinoma

DRIM modulates Src activation and regulates angiogenic functions in vascular endothelial cells

The Prognostic Significance of RIMKLB and Related Immune Infiltrates in Colorectal Cancers.

TRIM69: a Marker of Metastasis and Potential Sensitizer to 5-Fluorouracil and PD-1 Blockers in Colon Adenocarcinoma

PIM3 Functions As Oncogenic Factor and Promotes the Tumor Growth and Metastasis in Colorectal Cancer

TRIM59 facilitates the proliferation of colorectal cancer and promotes metastasis via the PI3K/AKT pathway

Up-regulation of Tripartite Motif-Containing 29 Promotes Cancer Cell Proliferation and Predicts Poor Survival in Colorectal Cancer

[Relationship Between the Expression of DDX39 Protein and Prognosis of Colorectal Cancer].

Expression and Clinical Significance of TRIM55 in Colorectal Cancer

Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment

Tripartite motif-containing 15 overexpression in non-small cell lung cancer is associated with poor patient prognoses.

TRIM59 Overexpression Correlates with Poor Prognosis and Contributes to Breast Cancer Progression Through AKT Signaling Pathway.

Expression of Tripartite Motif-Containing Proteactiin 11 (TRIM11) is Associated with the Progression of Human Prostate Cancer and is Downregulated by MicroRNA-5193.

Role of disulfidptosis in colorectal adenocarcinoma: implications for prognosis and immunity

Potential role of TRIM3 as a novel tumour suppressor in colorectal cancer (CRC) development

TRIM39 Deficiency Inhibits Tumor Progression and Autophagic Flux in Colorectal Cancer Via Suppressing the Activity of Rab7.